Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 513 of 6351
-
Radiation after surgery may keep tongue cancer at bay for High-Risk patients
Disease control Recruiting nowThe goal of this clinical trial is to learn whether postoperative radiotherapy can delay disease recurrence in patients with early-stage oral squamous cell carcinoma who have high-risk factors. The main question it aims to answer is: Is the clinical outcome of early-stage tongue …
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Gene-Editing shot aims to tame deadly fat levels in kids
Disease control Recruiting nowThis is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents (4-18 years) With Hyperchylomicronemia
Early phase 1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
In-Body CAR-T: could this be the future of blood cancer treatment?
Disease control Not yet recruitingMalignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractor…
Early phase 1 • Sponsor: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThe purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be …
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill could ease painful skin bumps in hidradenitis suppurativa
Disease control Recruiting nowHidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abs…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a stomach acid blocker shield stroke patients from bleeding?
Disease control Recruiting nowPatients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, n…
Phase 3 • Sponsor: Hanyang University Guri Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill combo aims to fight advanced cancers that stopped responding to prior therapies
Disease control Recruiting nowThis study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and c…
Phase 1/2 • Sponsor: Aminex Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could early blood thinner save more heart attack patients?
Disease control Recruiting nowThis randomized, multicenter, prospective trial will enroll 6,294 participants in approximately 80 centers. STEMI patients with onset time within 12 hours and scheduled for primary PCI will be randomly assigned to two groups in a 1:1 ratio. Patients meeting the criteria were rand…
Sponsor: Chen Jing • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a common immune treatment save lives during sudden lung scarring attacks?
Disease control Recruiting nowAcute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events. Inflammation and immune system imbalance are thought to pl…
Phase 3 • Sponsor: Argyrios Tzouvelekis • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail may replace bone marrow transplant for some leukemia patients
Disease control Recruiting nowThis clinical trial aims to evaluate whether molecular MRD-guided chemotherapy can effectively treat FLT3-ITD mutated AML and potentially replace allogeneic hematopoietic stem cell transplantation. It primarily seeks to answer: * What is the complete remission rate after initial…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects releva…
Early phase 1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New combo therapy aims to turn inoperable liver cancer into operable
Disease control Not yet recruitingThis is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (…
Sponsor: Ningbo Medical Center Lihuili Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launched
Disease control Recruiting nowA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
Phase 3 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Weight-Loss drug retatrutide shows promise in phase 3 trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cocktail of drugs takes on advanced lung cancer
Disease control Recruiting nowThis is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficac…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New asthma drug aims to cut severe attacks in half
Disease control Recruiting nowThis study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, includi…
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for Treatment-Resistant schizophrenia? phase 3 trial launches
Symptom relief Recruiting nowThis is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophre…
Phase 3 • Sponsor: Newron Pharmaceuticals SPA • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
One-and-Done: new MRI-Guided radiation could transform liver cancer treatment
Disease control Recruiting nowSingle arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for advanced bladder cancer: maintenance therapy after combo treatment
Disease control Recruiting nowThis is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial c…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingToripalimab and bevacizumab (T-B) was approve for unresectable hepatocellular carcinoma (uHCC). Transartial therapies, including transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), and TACE-HAIC are commonly used for uHCC. Increasing evidence show…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC